Global Cancer Immunotherapies Markets, 2017 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation

The report "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.Specifically, this report:

The report "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report:

Scope

Key Topics Covered:

1 Table of Contents

2 Executive Summary
2.1 A Large Therapy Area with Varying Unmet Needs across Indications
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation

3 The Case for Innovation in the Oncology Market
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance

4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.1.1 Epidemiology
4.1.2 Etiology
4.1.3 Pathophysiology
4.1.4 Diagnosis
4.1.5 Prognosis and Disease Staging
4.2 Treatment Options
4.2.1 Surgery
4.2.2 Radiation Therapy
4.2.3 Chemotherapy
4.2.4 Hormonal Therapies
4.2.5 Targeted Therapies
4.2.6 Immunotherapies
4.3 Overview of Marketed Products within Cancer Immunotherapy
4.4 Current Unmet Needs across the Oncology Markets

5 Assessment of Pipeline Product Innovation
5.1 Cancer Immunotherapies Pipeline by Phase, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.3.1 First-in-Class Cancer Immunotherapy Products by Phase, Molecule Type and Molecular Target

6 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.1 The Complexity of Signaling Networks in Oncology
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Target Matrix Assessment

7 First-in-Class Target Assessment
7.1 Pipeline Programs that Target Low-Affinity Immunoglobulin Gamma Fc Region Receptor IIIA
7.2 Pipeline Programs that Target Programmed Death 1 Ligand-2
7.3 Pipeline Programs that Target OX-2 Membrane Glycoprotein/CD200
7.4 Pipeline Programs that Target Killer-Cell Immunoglobulin-Like Receptors
7.5 Pipeline Programs that Target Toll-Like Receptors
7.6 Pipeline Programs that Target Inducible T-Cell Costimulator
7.7 Pipeline Programs that Target Membrane Cofactor Protein
7.8 Pipeline Programs that Target NKG2-A/NKG2-B Type II Integral Membrane Protein
7.9 Pipeline Programs that Target Stimulator of Interferon Genes Protein
7.10 Conclusion

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.2 Co-development Deals

9 Appendix
9.1 Abbreviations
9.2 References
9.3 Research Methodology
9.3.1 Data Integrity
9.3.2 Innovative and Meaningful Analytical Technique and Frameworks
9.3.3 Evidence-based Analysis and Insight
9.4 Secondary Research
9.4.1 Market Analysis
9.4.2 Pipeline Analysis
9.4.3 First-in-Class Matrix Assessment
9.4.4 First-in-Class Target Profiles
9.4.5 Licensing and Co-Development Deals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3fcmmt/frontier_pharma

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716